Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial

PURPOSE: Sorafenib is a kinase inhibitor targeting Raf and other kinases (ie, vascular endothelial growth factor receptor [VEGFR], platelet-derived growth factor receptor [PDGFR], Flt3, and c-KIT). This study assessed its activity and tolerability in patients with recurrent ovarian cancer (OC) or pr...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Matei, Daniela, Sill, Michael W., Lankes, Heather A., DeGeest, Koen, Bristow, Robert E., Mutch, David, Yamada, S. Diane, Cohn, David, Calvert, Valerie, Farley, John, Petricoin, Emanuel F., Birrer, Michael J.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2011
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3055861/
https://ncbi.nlm.nih.gov/pubmed/21098323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.26.7856
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires